ILK: A Potential Drug Target for Various Diseases (G3611)

Target Name: ILK

NCBI ID: G3611

Content of Review Report on ILK Target / Biomarker

ILK

ILK: A Potential Drug Target for Various Diseases

ILK (Integrin-like kinase) is a 59 kDa serine/threonine-protein kinase that is expressed in various cell types, including neutrophils, endothelial cells, and epithelial cells. It plays a crucial role in cell signaling, particularly in the regulation of cell adhesion, migration, and invasion.

The ILK kinase is composed of a catalytic domain and two transmembrane regions. The catalytic domain is responsible for the kinetic events, while the transmembrane regions are involved in the regulation of the activity of the enzyme. The ILK kinase has been shown to play a key role in the regulation of cell adhesion and migration, as well as in the regulation of cell growth and differentiation.

One of the unique features of ILK is its ability to interact with various cell surface molecules, including integrins, cadherins, and vimentin. This interaction with these molecules allows ILK to regulate the activity of cells that are in close proximity to each other. ILK has been shown to play a critical role in the regulation of cell adhesion, as well as in the regulation of cell migration and the establishment of tissue structures.

In addition to its role in cell signaling, ILK has also been shown to have potential as a drug target. The high level of expression of ILK in various tissues makes it an attractive target for small molecule inhibitors. Several studies have shown that inhibitors of ILK have been effective in preventing the migration and invasion of various cell types, including cancer cells.

The identification of small molecules that can inhibit the activity of ILK has important implications for the development of new treatments for various diseases. For example, inhibitors of ILK have been shown to be effective in preventing the growth and spread of cancer cells in various models. Additionally, the regulation of ILK activity has been implicated in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

In conclusion, ILK is a 59 kDa serine/threonine-protein kinase that plays a critical role in cell signaling and regulation. Its interaction with various cell surface molecules makes it an attractive target for small molecule inhibitors. The regulation of ILK activity has been implicated in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Therefore, the development of new treatments for these diseases may be greatly improved by targeting the ILK kinase.

Protein Name: Integrin Linked Kinase

Functions: Receptor-proximal protein kinase regulating integrin-mediated signal transduction (PubMed:8538749, PubMed:9736715). May act as a mediator of inside-out integrin signaling (PubMed:10712922). Focal adhesion protein part of the complex ILK-PINCH (PubMed:10712922). This complex is considered to be one of the convergence points of integrin- and growth factor-signaling pathway (PubMed:10712922). Could be implicated in mediating cell architecture, adhesion to integrin substrates and anchorage-dependent growth in epithelial cells (PubMed:10712922). Regulates cell motility by forming a complex with PARVB (PubMed:32528174). Phosphorylates beta-1 and beta-3 integrin subunit on serine and threonine residues, but also AKT1 and GSK3B (PubMed:8538749, PubMed:9736715)

The "ILK Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ILK comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets